Naproxen disposition in hepatic and biliary disorders.
The pharmacokinetics of Naproxen have been studied in 11 patients diagnosed with various hepatic and biliary disorders after oral administration of a single dose of 250 mg of the drug. The drug is seen to follow an open two-compartment model. In relation to the values obtained from healthy volunteers, it may be seen that in these patients there are modifications in the absorption, distribution and elimination of the drug. In certain of the patients with cholestasis, a significant delay in absorption may be observed. In most of the patients studied, elimination is clearly diminished due to a decrease in the capacity to biotransform the drug within the organism. In healthy volunteers, the plasma half-life of the beta-phase has an average value of 14.14 hrs while in patients it reaches a value of 20.36 hrs.
D002779:Cholestasis / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008107:Liver Diseases / Q000378:metabolism; D008111:Liver Function Tests; D009288:Naproxen / Q000097:blood / Q000378:metabolism*
D009288:Naproxen